Trinity Biotech (TRIB) Downgraded by ValuEngine to Strong Sell

Trinity Biotech (NASDAQ:TRIB) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Thursday.

Separately, Zacks Investment Research lowered Trinity Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th.

TRIB stock opened at $4.99 on Thursday. The company has a current ratio of 5.30, a quick ratio of 3.76 and a debt-to-equity ratio of 1.45. The stock has a market capitalization of $119.96, a price-to-earnings ratio of 19.19 and a beta of 1.31. Trinity Biotech has a 1 year low of $4.22 and a 1 year high of $6.54.



Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings results on Wednesday, March 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.01. The company had revenue of $24.55 million for the quarter, compared to analyst estimates of $23.53 million. Trinity Biotech had a positive return on equity of 2.37% and a negative net margin of 40.62%. equities analysts forecast that Trinity Biotech will post 0.07 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of TRIB. Deutsche Bank AG raised its position in Trinity Biotech by 3,969,200.0% in the 4th quarter. Deutsche Bank AG now owns 39,693 shares of the company’s stock valued at $202,000 after purchasing an additional 39,692 shares in the last quarter. State Street Corp raised its position in Trinity Biotech by 2.1% in the 2nd quarter. State Street Corp now owns 37,614 shares of the company’s stock valued at $225,000 after purchasing an additional 781 shares in the last quarter. Fondren Management LP acquired a new stake in Trinity Biotech in the 4th quarter valued at about $510,000. Renaissance Technologies LLC raised its position in Trinity Biotech by 43.2% in the 4th quarter. Renaissance Technologies LLC now owns 398,850 shares of the company’s stock valued at $2,034,000 after purchasing an additional 120,400 shares in the last quarter. Finally, Millennium Management LLC raised its position in Trinity Biotech by 20.8% in the 4th quarter. Millennium Management LLC now owns 403,587 shares of the company’s stock valued at $2,058,000 after purchasing an additional 69,469 shares in the last quarter. 62.08% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://dakotafinancialnews.com/2018/04/14/trinity-biotech-trib-downgraded-by-valuengine-to-strong-sell.html.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply